Navigation Links
Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
Date:8/17/2010

CRANBURY, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

As part of the analysis of the effects of bremelanotide on blood pressure, the Company engaged an independent panel of cardiovascular experts to evaluate both study results and an integrated cardiovascular safety analysis conducted on data from completed bremelanotide studies. Based on recommendations from the outside panel and its own internal review, Palatin intends to engage the Food and Drug Administration (FDA) in discussions regarding clinical trial designs to further study bremelanotide for the treatment of sexual dysfunction.

Palatin expects to meet with the FDA in the fourth quarter of calendar year 2010 to discuss initiation of a Phase 2 study of subcutaneously administered bremelanotide, as a monotherapy and as a combination therapy with a PDE-5 inhibitor such as sildenafil (Viagra®), for men with ED who are not responsive or inadequately responsive to PDE-5 inhibitor therapies alone.  

The objective of the placebo-controlled, randomized, double-blind, cross over safety study was evaluation of blood pressure effects of subcutaneous bremelanotide in healthy male volunteers between 45 and 65 years old.  The study also evaluated dose-to-dose consistency of plasma exposure of bremelanotide.  A total of 49 subjects were dosed in the safety study; nineteen of the subjects were enro
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Kim Foerster Joins Lockton Companies 2
... , , , ROGERS, Minn. ... conclude the new ionator EXP™ and ionator HOM™ kill the ... virus with a product that simply ionizes tap water. Slightly ... HOM™ from Activeion Cleaning Solutions, are handheld, on-demand cleaning and ...
... NEWTON, Mass. , Jan. 13 Microfluidics ... ( Burlington, Ontario ) to be the exclusive distributor of ... majority of Canada . ATS, which recently celebrated its ... a portfolio of synergistic products, including HORIBA particle size analyzers. ...
Cached Medicine Technology:New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals 2New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals 3Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada 2Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada 3
(Date:12/26/2014)... December 26, 2014 Plugin and template developers ... Volume 5 Plugin for Final Cut Pro X. , “TransPack ... light tool to pull off an industry professional look” Said ... their hands on TransPack Volume 5, a new level of ... a set of over 50 Final Cut Pro X transitions ...
(Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... Today, during the 39th Annual Meeting of ... the Walter E. Washington Convention Center in Washington, ... Lexington) will present a poster of a study ... induce HIV-1 Reactivation." Although oral co-infections (e.g. periodontal ...
... ... ... ... ...
... with heart disease most susceptible to potential problems, small study ... could raise the risk for experiencing heartbeat irregularities among older ... suggests. , The finding stems from an assessment of a ... history of heart disease -- who were observed in an ...
... Food choices in years prior to illness may extend ... (HealthDay News) -- Healthy eating habits lead to longer ... In a study of 351 women with incident epithelial ... and vegetable consumption, higher vegetable consumption alone, and healthy ...
... ... ... , ... , , , ...
... ... ... ... ...
Cached Medicine News:Health News:Periodontal pathogens enhance HIV-1 promoter activation in T cells 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 4Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 5Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 2Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 3Health News:Pre-Diagnosis Diet Linked to Ovarian Cancer Survival 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 4Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 5Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 2Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 3Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 4Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 5Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 6Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 7Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 8Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 9Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 10Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 11
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: